menu
    • menu

    Find Olaparib manufacturers, exporters & distributors on PharmaCompass

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Olaparib

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    Contact Supplier

    Olaparib

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    45

    API Suppliers

    API Suppliers

    15

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    5

    EU WC

    EU WC

    6

    KDMF

    KDMF

    13

    NDC API

    NDC API

    0

    VMF

    NDC API

    25

    Listed Suppliers

    Other Suppliers

    39INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    13

    Others

    FINISHED DOSAGE FORMULATIONS

    45

    FDF Dossiers

    FDF Dossiers

    5

    FDA Orange Book

    FDA (Orange Book)

    7

    Europe

    Europe

    2

    Canada

    Canada

    22

    Australia

    Australia

    2

    South Africa

    South Africa

    7

    Listed Dossiers

    Listed Dossiers

    81DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    116RELATED EXCIPIENT COMPANIES

    226EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    117

    US Patents

    10

    US Exclusivities

    4

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 7,247

    GLOBAL SALES INFORMATION

    US Medicaid

    487,431,793

    Annual Reports

    20,976

    Regulatory FDF Prices

    Listed Dossiers
    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    9

    API

    5

    FDF

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    276

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 763113-22-0, Lynparza, Azd2281, Azd-2281, Ku-0059436, Azd 2281
    Molecular Formula
    C24H23FN4O3
    Molecular Weight
    434.5  g/mol
    InChI Key
    FDLYAMZZIXQODN-UHFFFAOYSA-N
    FDA UNII
    WOH1JD9AR8
    Olaparib
    Olaparib is a small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.
    Olaparib is a Poly(ADP-Ribose) Polymerase Inhibitor. The mechanism of action of olaparib is as a Poly(ADP-Ribose) Polymerase Inhibitor.
    1 2D Structure

    Olaparib

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
    2.1.2 InChI
    InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
    2.1.3 InChI Key
    FDLYAMZZIXQODN-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
    2.2 Other Identifiers
    2.2.1 UNII
    WOH1JD9AR8
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Azd 2281

    2. Azd-2281

    3. Azd221

    4. Azd2281

    5. Lynparza

    2.3.2 Depositor-Supplied Synonyms

    1. 763113-22-0

    2. Lynparza

    3. Azd2281

    4. Azd-2281

    5. Ku-0059436

    6. Azd 2281

    7. 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine

    8. Olaparib (azd-2281)

    9. 4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2h)-one

    10. Ku-59436

    11. Olaparib (azd2281, Ku-0059436)

    12. 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2h-phthalazin-1-one

    13. Az2281

    14. Mfcd13185161

    15. Woh1jd9ar8

    16. Nsc-747856

    17. C24h23fn4o3

    18. Chebi:83766

    19. 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2h)-one

    20. 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one

    21. Az-2281

    22. Keylynk-010 Component Olaparib

    23. Ku59436

    24. Olaparib Component Of Keylynk-010

    25. Olaparib [inn]

    26. Olaparib Cpd

    27. Olaparib (azd2281; Ku-0059436)

    28. Olaparib [usan:inn]

    29. Unii-woh1jd9ar8

    30. Olaparib (azd2281)

    31. Acylpiperazine Analogue, 47

    32. Olaparibum

    33. Azd221

    34. 4-[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2h)-one

    35. Olaparib- Bio-x

    36. Lynparza (tn)

    37. 09l

    38. 4-((3-((4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl)-4-fluorophenyl)methyl)phthalazin-1(2h)-one

    39. 4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2h)-one

    40. 4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2h)-one

    41. Ku 59436

    42. Olaparib [usan]

    43. Olaparib [jan]

    44. Ku0059436

    45. Olaparib [mi]

    46. Olaparib [vandf]

    47. Olaparib - Azd2281

    48. Olaparib [mart.]

    49. Olaparib [who-dd]

    50. Azd-2281 (olaparib)

    51. Olaparib (jan/usan/inn)

    52. Mls006010185

    53. Schembl426568

    54. Olaparib [orange Book]

    55. Chembl521686

    56. Gtpl7519

    57. Bdbm27566

    58. Dtxsid60917988

    59. Ex-a002

    60. Bcpp000360

    61. Hms3295i09

    62. Hms3426c03

    63. Hms3654g13

    64. Hms3746k07

    65. Hms3870h03

    66. Amy10295

    67. Bcp01872

    68. 763113-22-0, Lynparza,

    69. Nsc747856

    70. Nsc753686

    71. S1060

    72. Zinc40430143

    73. Akos005145764

    74. Ac-7939

    75. Bcp9000363

    76. Ccg-264799

    77. Cs-0075

    78. Db09074

    79. Ex-7210

    80. Nsc 747856

    81. Nsc-753686

    82. Sb14617

    83. Ss-4573

    84. Azd2281,olaparib, Ku-0059436

    85. Ncgc00238451-01

    86. Ncgc00238451-02

    87. Ncgc00238451-08

    88. Ncgc00238451-09

    89. Ncgc00238451-11

    90. 4-[(3-{[4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2h)-one

    91. 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2h)-phthalazinone

    92. Bo164169

    93. Hy-10162

    94. Smr004701291

    95. Sy040527

    96. Olaparib(azd2281,kudosku-0059436)

    97. A9666

    98. Bb 0260909

    99. Ft-0651458

    100. Ku 0059436

    101. Sw218142-2

    102. Ec-000.2324

    103. D09730

    104. J-503540

    105. Q7083106

    106. Brd-k02113016-001-08-9

    107. Brd-k02113016-001-09-7

    108. 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazine

    109. 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2h)-one

    110. (2h)-phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-

    111. 1(2h)-phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-

    112. 1021843-02-6

    113. 4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one

    114. Piperazine, 1-(cyclopropylcarbonyl)-4-(5-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)-2-fluorobenzoyl)-

    2.4 Create Date
    2008-02-11
    3 Chemical and Physical Properties
    Molecular Weight 434.5 g/mol
    Molecular Formula C24H23FN4O3
    XLogP31.9
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count4
    Exact Mass434.17541877 g/mol
    Monoisotopic Mass434.17541877 g/mol
    Topological Polar Surface Area82.1 Ų
    Heavy Atom Count32
    Formal Charge0
    Complexity790
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of: - Ovarian cancer, in which the medication is intended for [a] the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy, or [b] for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for olaparib. - Breast cancer, in which the medication is intended for use in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment. Select patients for therapy based on an FDA-approved companion diagnostic for olaparib.

    FDA Label

    * Ovarian cancer :

    Lynparza is indicated as monotherapy for the:

    - maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

    - maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

    Lynparza in combination with bevacizumab is indicated for the:

    - maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5. 1).

    * Breast cancer :

    Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer . Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5. 1).

    Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.

    * Adenocarcinoma of the pancreas:

    Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.

    * Prostate cancer :

    Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.

    Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum based chemotherapy.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    The effect of olaparib on cardiac repolarization was assessed in 119 patients following a single dose of 300 mg and in 109 patients following multiple dosing of 300 mg twice daily. No clinically relevant effect of olaparib on QT interval was observed.

    5.2 MeSH Pharmacological Classification

    Antineoplastic Agents

    Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

    Poly(ADP-ribose) Polymerase Inhibitors

    Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. (See all compounds classified as Poly(ADP-ribose) Polymerase Inhibitors.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    OLAPARIB
    5.3.2 FDA UNII
    WOH1JD9AR8
    5.3.3 Pharmacological Classes
    Poly(ADP-Ribose) Polymerase Inhibitors [MoA]; Poly(ADP-Ribose) Polymerase Inhibitor [EPC]
    5.4 ATC Code

    L01XK01

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01X - Other antineoplastic agents

    L01XK - Poly (adp-ribose) polymerase (parp) inhibitors

    L01XK01 - Olaparib

    5.5 Absorption, Distribution and Excretion

    Absorption

    Following oral administration, the absorption of olaparib is very rapid and can reach a peak concentration ranging between 4.7 and 9.1 mcg/ml after 1-3 hours. The reported AUC of olaparib after a dose of 200 mg is of 25.8 mcg.h/L and this AUC can be increased by 26% with constant administration. The consumption of a high-fat diet with olaparib can only decrease the tmax but do not have an effect in the peak concentration.

    Route of Elimination

    From the administered dose, approximately 86% of the administered dose is recovered after 7 days from which 44% is found in the urine and 42% is obtained in feces.

    Volume of Distribution

    After administration of a dose of 100 mg/kg, the reported volume of distribution was of 40.3 L.

    Clearance

    The total clearance of olaparib was reported to be 4.6 L/h.

    5.6 Metabolism/Metabolites

    Olaparib is extensively metabolized in the liver by the action of CYP3A isoenzymes. From the administered dose, the unchanged form of olaparib accounted for 70% of the circulating dose and it was considered the major component in urine and feces. The metabolic pathway of olaparib is mainly attributable to oxidation reactions with subsequent glucuronide and sulfate conjugation. However, the over 20 metabolites found in plasma, urine, and feces represented a minor portion of the administered dose. The major circulating metabolites were represented by the mono-oxygenated form and the piperazin-3-ol form.

    5.7 Biological Half-Life

    The reported elimination half-life ranges between 5 to 11 hours.

    5.8 Mechanism of Action

    Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.

    USDMF

    read-more
    read-moreread-more

    01

    Dr Reddys Laboratories Ltd

    India
    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GDUFA

    DMF Review : Complete

    Rev. Date : 2022-04-19

    Pay. Date : 2022-03-31

    DMF Number : 35742

    Submission : 2021-03-30

    Status : Active

    Type : II

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Biophore India Pharmaceuticals Pvt L...

    India
    arrow
    iPHEX India
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40467

    Submission : 2024-09-28

    Status : Active

    Type : II

    Biophore

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    APGA Annual Conference
    Not Confirmed

    03

    Alembic Pharmaceuticals Ltd

    India
    arrow
    APGA Annual Conference
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2018-05-31

    Pay. Date : 2018-02-22

    DMF Number : 32505

    Submission : 2018-03-28

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    APGA Annual Conference
    Not Confirmed

    04

    Alp Pharm Beijing Co Ltd

    China
    arrow
    APGA Annual Conference
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 31219

    Submission : 2016-12-15

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Cipla Ltd

    India

    USDMF

    arrow
    APGA Annual Conference
    Not Confirmed

    05

    Cipla Ltd

    India
    arrow
    APGA Annual Conference
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2022-08-29

    Pay. Date : 2022-08-10

    DMF Number : 37240

    Submission : 2022-08-01

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Hetero Labs Ltd

    India

    USDMF

    arrow
    APGA Annual Conference
    Not Confirmed

    06

    Hetero Labs Ltd

    India
    arrow
    APGA Annual Conference
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 35831

    Submission : 2021-04-17

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    APGA Annual Conference
    Not Confirmed

    07

    Msn Laboratories Private Ltd

    India
    arrow
    APGA Annual Conference
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2023-10-12

    Pay. Date : 2023-08-29

    DMF Number : 34698

    Submission : 2020-03-31

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Olon Spa

    Italy

    USDMF

    arrow
    APGA Annual Conference
    Not Confirmed

    08

    Olon Spa

    Italy
    arrow
    APGA Annual Conference
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2023-03-21

    Pay. Date : 2022-12-22

    DMF Number : 37779

    Submission : 2023-02-09

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Scinopharm Taiwan Ltd

    Taiwan

    USDMF

    arrow
    APGA Annual Conference
    Not Confirmed

    09

    Scinopharm Taiwan Ltd

    Taiwan
    arrow
    APGA Annual Conference
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2018-11-16

    Pay. Date : 2018-09-27

    DMF Number : 32629

    Submission : 2018-04-20

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    APGA Annual Conference
    Not Confirmed

    10

    Shandong Anhong Pharmaceutical Co Lt...

    China
    arrow
    APGA Annual Conference
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2023-07-10

    Pay. Date : 2023-06-08

    DMF Number : 38395

    Submission : 2023-06-18

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    NDC API

    read-more
    read-moreread-more

    01

    Dr. Reddy’s Laboratories Limited

    India
    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    NDC Package Code : 71796-034

    Start Marketing Date : 2021-11-01

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Alembic Pharmaceuticals Limited

    India
    APGA Annual Conference
    Not Confirmed
    arrow

    Alembic Pharmaceuticals Limited

    India
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    NDC Package Code : 46708-904

    Start Marketing Date : 2018-03-15

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (25kg/25kg)

    Marketing Category : BULK INGREDIENT

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    DOTTIKON EXCLUSIVE SYNTHESIS AG

    Switzerland
    APGA Annual Conference
    Not Confirmed
    arrow

    DOTTIKON EXCLUSIVE SYNTHESIS AG

    Switzerland
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    NDC Package Code : 54864-843

    Start Marketing Date : 2017-08-18

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Hetero Labs Limited

    India
    APGA Annual Conference
    Not Confirmed
    arrow

    Hetero Labs Limited

    India
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    NDC Package Code : 68554-0120

    Start Marketing Date : 2014-12-19

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Lonza AG

    U.S.A
    APGA Annual Conference
    Not Confirmed
    arrow

    Lonza AG

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    NDC Package Code : 49187-0741

    Start Marketing Date : 2018-01-19

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Lonza AG

    U.S.A
    APGA Annual Conference
    Not Confirmed
    arrow

    Lonza AG

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    NDC Package Code : 49187-0740

    Start Marketing Date : 2011-01-01

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    MSN Laboratories Private Limited

    India
    APGA Annual Conference
    Not Confirmed
    arrow

    MSN Laboratories Private Limited

    India
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    NDC Package Code : 54893-0099

    Start Marketing Date : 2020-03-30

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Olon S.p.A.

    Italy
    APGA Annual Conference
    Not Confirmed
    arrow

    Olon S.p.A.

    Italy
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    NDC Package Code : 17337-0319

    Start Marketing Date : 2022-12-16

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    ScinoPharm Taiwan Ltd.

    Taiwan
    APGA Annual Conference
    Not Confirmed
    arrow

    ScinoPharm Taiwan Ltd.

    Taiwan
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Taiwan
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    NDC Package Code : 65129-1464

    Start Marketing Date : 2018-05-18

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    ScinoPharm Taiwan Ltd.

    Taiwan
    APGA Annual Conference
    Not Confirmed
    arrow

    ScinoPharm Taiwan Ltd.

    Taiwan
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Taiwan
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    NDC Package Code : 65129-1400

    Start Marketing Date : 2018-05-18

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Suppliers

    read-more
    read-more

    01

    Dr. Reddy's Laboratories

    India
    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...

    Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfolio that provides high-quality, low-cost APIs to leading pharma companies in 80+ countries. It has 8 USFDA-inspected facilities – 6 in India & 1 each in Mexico & the UK & are inspected by international regulatory authorities on a regular basis. Its facilities are supplemented by formulation facilities that provide a wide range of dosage forms. Product(s) under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale
    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Kinsy SL

    Spain
    arrow
    Biospain
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothReliable Spanish CDMO Delivering High-Quality APIs and Intermediates with Excellence, Flexibility, and Regulatory Compliance.

    Contact Supplier Contact Supplier
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Kinsy, an independent CDMO in Spain, offers over 30 years of expertise in developing and manufacturing advanced pharmaceutical intermediates and APIs. We provide innovative route d...

    Kinsy, an independent CDMO in Spain, offers over 30 years of expertise in developing and manufacturing advanced pharmaceutical intermediates and APIs. We provide innovative route development, analytical method optimization, pilot plant scale-up, and clinical-phase production with advanced purification techniques. Our services include process validation, commercial-scale manufacturing (>100 MT/year), and regulatory support (DMF, CEP, REACH). ISO 9001-certified and operating under cGMP standards audited by AEMPS, we are a trusted partner to leading global pharmaceutical companies.
    Kinsy SL Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Axplora

    Germany
    arrow
    PREP
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothAxplora is your partner of choice for complex APIs.

    Contact Supplier Contact Supplier
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-qual...

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.
    Axplora CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    LGM Pharma

    U.S.A
    arrow
    ChemOutsourcing
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...

    LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, analytical method development and testing, and commercial manufacturing. LGM Pharma offers custom API synthesis, analytical development, and regulatory services. With a network of over 300 accredited CGMP manufacturing partners, LGM provides unparalleled supply chain security. And, with over 100,000 square feet of FDA-inspected cGMP manufacturing and warehouse capacity, LGM Pharma provides a one-stop solution for solid dose, powder, semi-solid and liquid drugs.
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Rochem International Inc

    U.S.A
    arrow
    CPhI WW Frankfurt
    Booth #12.0F117
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothRochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...

    Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quality ingredients manufactured in China. Headquartered in the Hauppauge, New York, Rochem has 16 offices spread across the globe to cater to the needs of its customers. Rochem’s operations are fully cGMP compliant and has been audited by the USFDA as well as several multinational organizations. It also trains and audits its partners to ensure all of their technologies and systems are FDA-compliant.
    Rochem

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Aarti Pharmalabs

    India
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cyto...

    Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cytotoxic & oncology products. It has 2 R&D centers & 3 cGMP plants successfully audited by the USFDA, EUGMP, EDQM, KFDA & COFEPRIS. It offers CDMO services for generic APIs & NCEs, intermediates & key building blocks.Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
    Aarti Industries Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Jinan Tantu Chemicals

    China
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...

    Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include customized R&D as well as the production of small molecule pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) for both international and domestic pharmaceutical firms. Our capabilities span from laboratory-scale kilograms to commercial ton-scale production. Additionally, we are committed to independent research and development, as well as the production and sales of high-end pharmaceutical intermediates and API products.
    Jinan Tantu Chemicals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Shanghai Minbiotech

    China
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...

    ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry.
    Shanghai Minbiotech CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Aurore Life Sciences

    India
    APGA Annual Conference
    Not Confirmed
    arrow

    Aurore Life Sciences

    India
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2017 by a team with...

    Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2017 by a team with vast experience across the pharmaceutical value chain, the company is on a mission to become the most preferred partner for pharmaceuticals. At Aurore, we aim to push the boundaries to manufacture and deliver high quality products that can be relied upon by both customers and regulators. Our thrust on rapidly adding capabilities have led us to acquire, integrate and expand our reach across the geographies.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Cdymax

    India
    APGA Annual Conference
    Not Confirmed
    arrow

    Cdymax

    India
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olaparib

    About the Company : Cdymax (India) Pharma Private Limited was founded in 1994. The company's line of business includes the manufacturing, fabricating, or processing of drugs in pharmaceutical preparat...

    Cdymax (India) Pharma Private Limited was founded in 1994. The company's line of business includes the manufacturing, fabricating, or processing of drugs in pharmaceutical preparations for human or veterinary use.CDYMAX ensures and adherence to HSE practices. System and procedures are in place to control and monitoring. All employees under go periodic health check-up once in a year and twice in a year for oncology employees. Effluent treatment plant meeting Government regulation.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1642357800,"product":"OLAPARIB","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"12500","totalValueFC":"36902.6","currency":"USD","unitRateINR":916333.33333333337,"date":"17-Jan-2022","totalValueINR":"2749000","totalValueInUsd":"36902.6","indian_port":"AHMEDABAD AIR","hs_no":"29331999","bill_no":"7529366","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1653589800,"product":"OLAPARIB","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"AMMAN","customer":"UNDISCLOSED","customerCountry":"JORDAN","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"9000","totalValueFC":"22177.4","currency":"USD","unitRateINR":685600,"date":"27-May-2022","totalValueINR":"1714000","totalValueInUsd":"22177.4","indian_port":"AHMEDABAD AIR","hs_no":"29331999","bill_no":"1704900","productDescription":"API","marketType":"","country":"JORDAN","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1657132200,"product":"OLAPARIB","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SEOUL","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"12000","totalValueFC":"3433.2","currency":"USD","unitRateINR":910000,"date":"07-Jul-2022","totalValueINR":"273000","totalValueInUsd":"3433.2","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"2676561","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662575400,"product":"OLAPARIB API- BATCH NO. ON0030621 AS PER","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO SUNDIA","customerCountry":"UNITED STATES","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"7815.2","totalValueFC":"18667.1","currency":"USD","unitRateINR":598400,"date":"08-Sep-2022","totalValueINR":"1496000","totalValueInUsd":"18667.1","indian_port":"AHMEDABAD AIR","hs_no":"29337990","bill_no":"4040233","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662575400,"product":"OLAPARIB API- BATCH NO.ON0040721 AS PER","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO SUNDIA","customerCountry":"UNITED STATES","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"7815.2","totalValueFC":"18667.1","currency":"USD","unitRateINR":598400,"date":"08-Sep-2022","totalValueINR":"1496000","totalValueInUsd":"18667.1","indian_port":"AHMEDABAD AIR","hs_no":"29337990","bill_no":"4040233","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662575400,"product":"OLAPARIB API- BATCH NO.ON0050721 AS PER","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO SUNDIA","customerCountry":"UNITED STATES","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"7815.2","totalValueFC":"18667.1","currency":"USD","unitRateINR":598400,"date":"08-Sep-2022","totalValueINR":"1496000","totalValueInUsd":"18667.1","indian_port":"AHMEDABAD AIR","hs_no":"29337990","bill_no":"4040233","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662575400,"product":"OLAPARIB HOT MELT EXTRUDES- BATCH NO.024","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO SUNDIA","customerCountry":"UNITED STATES","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"2350.8","totalValueFC":"1123","currency":"USD","unitRateINR":180000,"date":"08-Sep-2022","totalValueINR":"90000","totalValueInUsd":"1123","indian_port":"AHMEDABAD AIR","hs_no":"29337990","bill_no":"4040233","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663525800,"product":"OLAPARIB (FORM-H) ONB5 (ON)","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"AL SAHRA TRADE PETRO DMCC","customerCountry":"UNITED ARAB EMIRATES","quantity":"2.55","actualQuantity":"2.55","unit":"KGS","unitRateFc":"14730.8","totalValueFC":"36485.7","currency":"EURO","unitRateINR":1146666.6666666667,"date":"19-Sep-2022","totalValueINR":"2924000","totalValueInUsd":"36485.7","indian_port":"BOMBAY AIR","hs_no":"29337990","bill_no":"4276820","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1664735400,"product":"OLAPARIB (FORM-H) ONB5 (ON)","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"AL SAHRA TRADE PETRO DMCC","customerCountry":"UNITED ARAB EMIRATES","quantity":"2.55","actualQuantity":"2.55","unit":"KGS","unitRateFc":"14730.8","totalValueFC":"35535.4","currency":"EURO","unitRateINR":1146666.6666666667,"date":"03-Oct-2022","totalValueINR":"2924000","totalValueInUsd":"35535.4","indian_port":"BOMBAY AIR","hs_no":"29337990","bill_no":"4602292","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669660200,"product":"OLAPARIB PLACEBO","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"UNDISCLOSED","customerCountry":"RUSSIA","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"2","totalValueFC":"183.8","currency":"USD","unitRateINR":150,"date":"29-Nov-2022","totalValueINR":"15000","totalValueInUsd":"183.8","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"5806511","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669660200,"product":"OLAPARIB PREMIX IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"UNDISCLOSED","customerCountry":"RUSSIA","quantity":"12.00","actualQuantity":"12","unit":"KGS","unitRateFc":"2500","totalValueFC":"27385.5","currency":"USD","unitRateINR":186250,"date":"29-Nov-2022","totalValueINR":"2235000","totalValueInUsd":"27385.5","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"5806511","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1675881000,"product":"OLAPARIB","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"10500","totalValueFC":"20377.8","currency":"USD","unitRateINR":841500,"date":"09-Feb-2023","totalValueINR":"1683000","totalValueInUsd":"20377.8","indian_port":"AHMEDABAD AIR","hs_no":"29331999","bill_no":"7668165","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1678905000,"product":"OLAPARIB API","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO LLC","customerCountry":"UNITED STATES","quantity":"21.00","actualQuantity":"21","unit":"KGA","unitRateFc":"6648.5","totalValueFC":"138769.8","currency":"USD","unitRateINR":543517.61904761905,"date":"16-Mar-2023","totalValueINR":"11413870","totalValueInUsd":"138769.8","indian_port":"Ahmedabad-ZIPL-SEZ","hs_no":"29337990","bill_no":"4001590","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad-ZIPL-SEZ","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1687372200,"product":"OLAPARIB, B.NO. 2304003868, MFG.DT. MAY-","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"UNDISCLOSED","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"15000","totalValueFC":"4452.8","currency":"USD","unitRateINR":1219998.78,"date":"22-Jun-2023","totalValueINR":"365999.634","totalValueInUsd":"4452.8","indian_port":"BOMBAY AIR","hs_no":"29331999","bill_no":"0","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691519400,"product":"OLAPARIB BATCH NO;OLBB022001","address":"NA","city":"BANGALORE","supplier":"ACEBRIGHT INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"LOTUS PHARMACEUTICAL CO LTD","customerCountry":"TAIWAN","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"6000","totalValueFC":"8541.9","currency":"USD","unitRateINR":471721.614,"date":"09-Aug-2023","totalValueINR":"707582.421","totalValueInUsd":"8541.9","indian_port":"BANGALORE AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"NA, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1692642600,"product":"OLAPARIB IH","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,","city":"HYDERABAD,TELANGANA","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"MONTREAL","customer":"PHARMASCIENCE INC","customerCountry":"CANADA","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"8428.9","totalValueFC":"16728.3","currency":"USD","unitRateINR":692855,"date":"22-Aug-2023","totalValueINR":"1385710","totalValueInUsd":"16728.3","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000523","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1693247400,"product":"OLAPARIB - BATCH NO. OLP-23001, MANUFACTURING DT.","address":"S-553 GREATER KAILASH-II","city":"NEW DELHI","supplier":"SAI PHYTOCEUTICALS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"CARPE SCHEIDER Y CIA S A","customerCountry":"ARGENTINA","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"10.5","totalValueFC":"1036.1","currency":"USD","unitRateINR":858.28308000000004,"date":"29-Aug-2023","totalValueINR":"85828.308","totalValueInUsd":"1036.1","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"S-553 GREATER KAILASH-II, NEW DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1702924200,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"MUSCAT","customer":"SMART SUPPLY INTERNATIONAL LLC","customerCountry":"OMAN","quantity":"0.35","actualQuantity":"0.35","unit":"KGS","unitRateFc":"8000","totalValueFC":"2967.2","currency":"EURO","unitRateINR":705714.2857142858,"date":"19-Dec-2023","totalValueINR":"247000","totalValueInUsd":"2967.2","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"6153419","productDescription":"API","marketType":"","country":"OMAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703010600,"product":"OLAPARIB IH","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"AMEDART LLC","customerCountry":"RUSSIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"4789.6","totalValueFC":"4749.8","currency":"USD","unitRateINR":395385,"date":"20-Dec-2023","totalValueINR":"395385","totalValueInUsd":"4749.8","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000819","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1706553000,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"BIOPROFARMA BAGO S A","customerCountry":"ARGENTINA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"21000","totalValueFC":"5993.8","currency":"USD","unitRateINR":1660516.6666666667,"date":"30-Jan-2024","totalValueINR":"498155","totalValueInUsd":"5993.8","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"7118633","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1708540200,"product":"OLAPARIB BATCH NO;OLBB23003","address":"N0 116\/117, KIADB INDUSTRIAL AREA,","city":"BANGALORE","supplier":"CDYMAX INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"LOTUS PHARMACEUTICAL COLTD","customerCountry":"TAIWAN","quantity":"0.90","actualQuantity":"0.9","unit":"KGS","unitRateFc":"6000","totalValueFC":"5009.5","currency":"USD","unitRateINR":461842.2888888889,"date":"22-Feb-2024","totalValueINR":"415658.06","totalValueInUsd":"5009.5","indian_port":"Bangalore Air","hs_no":"29339990","bill_no":"7744186","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1718217000,"product":"OLAPARIB IH","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"NAN-T OU","customer":"LOTUS PHARMACEUTICAL CO LTD","customerCountry":"TAIWAN","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"8464.3","totalValueFC":"16750.3","currency":"USD","unitRateINR":699153.5,"date":"13-Jun-2024","totalValueINR":"1398307","totalValueInUsd":"16750.3","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000447","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1723573800,"product":"OLAPARIB IH","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,","city":"HYDERABAD,TELANGANA","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"NEWARK","customer":"RIA INTERNATIONAL LLC","customerCountry":"UNITED STATES","quantity":"2.95","actualQuantity":"2.95","unit":"KGS","unitRateFc":"10000","totalValueFC":"29046.6","currency":"USD","unitRateINR":825895.13898305083,"date":"14-Aug-2024","totalValueINR":"2436390.66","totalValueInUsd":"29046.6","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"3205305","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1728239400,"product":"OLAPARIB 1H","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"TUTEUR SACIFIA","customerCountry":"ARGENTINA","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"9000","totalValueFC":"264323.4","currency":"USD","unitRateINR":740339.33333333337,"date":"07-Oct-2024","totalValueINR":"22210180","totalValueInUsd":"264323.4","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"4642259","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1731349800,"product":"ACTIVEPHARMACEUTICALSINGREDIENTS(API)EXPORT INVOICENUMBER:F32512200871DT.08.11.2024 OLAPARIB","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK LIFE SCIENCES LTD","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO APT\/MOS","customer":"UNDISCLOSED","customerCountry":"RUSSIA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"756641","totalValueFC":"4348.8","currency":"INR","unitRateINR":733981,"date":"12-Nov-2024","totalValueINR":"366990.5","totalValueInUsd":"4348.8","indian_port":"Dahez-SEZ","hs_no":"29334900","bill_no":"5538644","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Dahez-SEZ","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1733077800,"product":"OLAPARIB (FORM-H) ONB5 (ON)","address":"A-2,419, CELEBRATION CITY CENTER,,","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"GLOBAL PROJECT CELIK SANAYU DIS TI","customerCountry":"TURKEY","quantity":"9.40","actualQuantity":"9.4","unit":"KGS","unitRateFc":"9105.9","totalValueFC":"84216.3","currency":"USD","unitRateINR":761252.08404255309,"date":"02-Dec-2024","totalValueINR":"7155769.59","totalValueInUsd":"84216.3","indian_port":"Bombay Air","hs_no":"29337990","bill_no":"6112943","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1733164200,"product":"OLAPARIB (FORM-H) ONB5 (ON)","address":"A-2,419, CELEBRATION CITY CENTER,,","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"GLOBAL PROJECT CELIK SANAYU DIS TI","customerCountry":"TURKEY","quantity":"9.40","actualQuantity":"9.4","unit":"KGS","unitRateFc":"9105.9","totalValueFC":"84216.3","currency":"USD","unitRateINR":761252.08404255309,"date":"03-Dec-2024","totalValueINR":"7155769.59","totalValueInUsd":"84216.3","indian_port":"Bombay Air","hs_no":"29337990","bill_no":"6120876","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1733423400,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS-(API)(PHARMACEUTICALS RAW MATERIAL) PRODUCT NAME-OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"MOSCOW","customer":"UNDISCLOSED","customerCountry":"RUSSIA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"3000","totalValueFC":"1120.3","currency":"USD","unitRateINR":190385.88,"date":"06-Dec-2024","totalValueINR":"95192.94","totalValueInUsd":"1120.3","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"6237307","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734978600,"product":"ACTIVE PHARMA INGREDIENTS (PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) PRODUCT NAME - OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"9500","totalValueFC":"46831.5","currency":"USD","unitRateINR":795844.54000000004,"date":"24-Dec-2024","totalValueINR":"3979222.7","totalValueInUsd":"46831.5","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"6711693","productDescription":"API","marketType":"REGULATED MARKET","country":"REPUBLIC OF KOREA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1736361000,"product":"OLAPARIB IH","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO APT\/MOS","customer":"AMEDART LLC","customerCountry":"RUSSIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"4572.1","totalValueFC":"4501.7","currency":"USD","unitRateINR":388175,"date":"09-Jan-2025","totalValueINR":"388175","totalValueInUsd":"4501.7","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000007","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1747593000,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TUTEUR S A C I F I A","customerCountry":"ARGENTINA","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"8075","totalValueFC":"238783.3","currency":"USD","unitRateINR":678149.65000000002,"date":"19-May-2025","totalValueINR":"20344489.5","totalValueInUsd":"238783.3","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"1955188","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1748284200,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS-(PHARMA RAW MATERIAL FOR PHARMA IND)PRODUCT-OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"TEL AVIV YAFO","customer":"UNDISCLOSED","customerCountry":"ISRAEL","quantity":"7.56","actualQuantity":"7.56","unit":"KGS","unitRateFc":"3500","totalValueFC":"25546","currency":"USD","unitRateINR":287901.68650793651,"date":"27-May-2025","totalValueINR":"2176536.75","totalValueInUsd":"25546","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"2196511","productDescription":"API","marketType":"","country":"ISRAEL","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1748370600,"product":"OLAPARIB (FORM-A) IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"MICROSULE ARGENTINA S.A.","customerCountry":"ARGENTINA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"9200","totalValueFC":"8991.4","currency":"USD","unitRateINR":766072,"date":"28-May-2025","totalValueINR":"766072","totalValueInUsd":"8991.4","indian_port":"Hyderabad Air","hs_no":"29334990","bill_no":"2211362","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1748889000,"product":"OLAPARIB BATCH NO:OLBD24001","address":"N0 116\/117, KIADB INDUSTRIAL AREA,","city":"BANGALORE","supplier":"CDYMAX INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"M\/S KRKA D.D NOVO MESTO","customerCountry":"SLOVENIA","quantity":"0.20","actualQuantity":"200","unit":"GMS","unitRateFc":"5.5","totalValueFC":"1012","currency":"USD","unitRateINR":434.79050000000001,"date":"03-Jun-2025","totalValueINR":"86958.1","totalValueInUsd":"1012","indian_port":"Bangalore Air","hs_no":"29335990","bill_no":"2393125","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1749493800,"product":"OLAPARIB","address":"A-2,419, CELEBRATION CITY CENTER,,","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"APRAMEYA PHARMACHEM FZCO","customerCountry":"UNITED ARAB EMIRATES","quantity":"21.00","actualQuantity":"21","unit":"KGS","unitRateFc":"3093.8","totalValueFC":"64307.9","currency":"USD","unitRateINR":263127.69,"date":"10-Jun-2025","totalValueINR":"5525681.49","totalValueInUsd":"64307.9","indian_port":"Bombay Air","hs_no":"29337990","bill_no":"2583959","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669055400,"product":"OLAPARIB (TEST LIC.NO. TL\/AZ\/22\/002729) FOR R & D PURPOSE NOT FOR SALE (FOC)","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"BIO DURO SUNDIA","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"ZYDUS LIFESCIENCES LTD","customerCountry":"INDIA","quantity":"0.05","actualQuantity":"0.05","unit":"KGS","unitRateFc":"7815.2","totalValueFC":"409.1","currency":"USD","unitRateINR":"667674.6","date":"22-Nov-2022","totalValueINR":"33383.73","totalValueInUsd":"409.1","indian_port":"BOMBAY AIR","hs_no":"29337990","bill_no":"3422337","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705948200,"product":"LUT-65 OLAPARIB FORMA A (CAS763113-22-0 IUPAC4-(3-(4-(CYCLOPROPANECARBONYL)PIPERAZINE-1-CARBONYL)-4-FLOROPHENYL)METHY","address":"SANDOZ HOUSE","city":"MUMBAI ,MAHARASHTRA","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"MILAN - MALPENSA","customer":"SANDOZ PRIVATE LTD","customerCountry":"INDIA","quantity":"23.73","actualQuantity":"23.73","unit":"KGS","unitRateFc":"6600","totalValueFC":"158480.4","currency":"USD","unitRateINR":"555060","date":"23-Jan-2024","totalValueINR":"13171573.8","totalValueInUsd":"158480.4","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"9785375","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"MILAN - MALPENSA","supplierAddress":"STR. RIVOLTANA KM 6\/720053 RODANO MI ITSDNF ITALY","customerAddress":"SANDOZ HOUSE"}]
    17-Jan-2022
    10-Jun-2025
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API/FDF Prices: Book a Demo to explore the features and consider upgrading later

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Pathos AI Raises $365M Series D to Boost Oncology Drug Discovery via AI

    Details:

    The proceeds will support advancement of the company’s clinical-stage pipeline, which includes FT-7051 (pocenbrodib) is being evaluated for metastatic castration-resistant prostate cancer.


    Lead Product(s): Pocenbrodib,Abiraterone Acetate,Olaparib

    Therapeutic Area: Oncology Brand Name: FT-7051

    Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

    Sponsor: Undisclosed

    Deal Size: $365.0 million Upfront Cash: Undisclosed

    Deal Type: Series D Financing May 15, 2025

    blank

    01

    Pathos

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Pathos

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pocenbrodib,Abiraterone Acetate,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : $365.0 million

    Deal Type : Series D Financing

    DEALS_DEV arrow-down

    Pathos AI Raises $365M Series D to Boost Oncology Drug Discovery via AI

    Details : The proceeds will support advancement of the company’s clinical-stage pipeline, which includes FT-7051 (pocenbrodib) is being evaluated for metastatic castration-resistant prostate cancer.

    Product Name : FT-7051

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    May 15, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    LYNPARZA® Shows Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial

    Details:

    Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of BRCA-mutated HER2-negative high-risk early breast cancer.


    Lead Product(s): Olaparib

    Therapeutic Area: Oncology Brand Name: Lynparza

    Study Phase: Phase IIIProduct Type: Cytotoxic Drug

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 11, 2024

    blank

    02

    AstraZeneca

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    AstraZeneca

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    LYNPARZA® Shows Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial

    Details : Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of BRCA-mutated HER2-negative high-risk early breast cancer.

    Product Name : Lynparza

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    December 11, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    AstraZeneca Pharma Gets nod for Sale, Distribution of Cancer Drug Lynparza

    Details:

    Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of advanced or recurrent endometrial cancer in adults.


    Lead Product(s): Olaparib,Durvalumab

    Therapeutic Area: Oncology Brand Name: Lynparza

    Study Phase: Approved FDFProduct Type: Cytotoxic Drug

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 27, 2024

    blank

    03

    AstraZeneca

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    AstraZeneca

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Olaparib,Durvalumab

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    AstraZeneca Pharma Gets nod for Sale, Distribution of Cancer Drug Lynparza

    Details : Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of advanced or recurrent endometrial cancer in adults.

    Product Name : Lynparza

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    November 27, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Eisbach Bio Secures CPRIT Grant to Advance Novel Cancer Therapeutic

    Details:

    The funds will support the clinical development of Eisbach's first-in-class allosteric small molecule inhibitor EIS-12656 targeting ALC1, to treat human cancers.


    Lead Product(s): EIS-12656,Olaparib

    Therapeutic Area: Oncology Brand Name: EIS-12656

    Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

    Sponsor: CPRIT

    Deal Size: $4.7 million Upfront Cash: Undisclosed

    Deal Type: Funding November 26, 2024

    blank

    04

    Eisbach Bio

    Denmark
    arrow
    APGA Annual Conference
    Not Confirmed

    Eisbach Bio

    Denmark
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : EIS-12656,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : CPRIT

    Deal Size : $4.7 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    Eisbach Bio Secures CPRIT Grant to Advance Novel Cancer Therapeutic

    Details : The funds will support the clinical development of Eisbach's first-in-class allosteric small molecule inhibitor EIS-12656 targeting ALC1, to treat human cancers.

    Product Name : EIS-12656

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    November 26, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Repare Doses First Patient in Phase 1 RP-3467 Trial Targeting Polθ in Cancer

    Details:

    RP-3467 is a Polθ ATPase inhibitor, small molecule drug candidate, which is being evaluated in combination with olaparib for the treatment of advanced solid tumors.


    Lead Product(s): RP-3467,Olaparib

    Therapeutic Area: Oncology Brand Name: RP-3467

    Study Phase: Phase IProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 14, 2024

    blank

    05

    Repare Therapeutics

    Canada
    arrow
    APGA Annual Conference
    Not Confirmed

    Repare Therapeutics

    Canada
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : RP-3467,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Repare Doses First Patient in Phase 1 RP-3467 Trial Targeting Polθ in Cancer

    Details : RP-3467 is a Polθ ATPase inhibitor, small molecule drug candidate, which is being evaluated in combination with olaparib for the treatment of advanced solid tumors.

    Product Name : RP-3467

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    October 14, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Eisbach Doses First Patient in Phase 1/2 Trial for EIS-12656 in Refractory Solid Tumors

    Details:

    EIS-12656 targets ALC1 through allosteric mechanisms, suppressing the cancer-relevant genome reorganization induced by DNA damage. This leads to ALC1 chromatin trapping and cancer cell killing.


    Lead Product(s): EIS-12656,Olaparib

    Therapeutic Area: Oncology Brand Name: EIS-12656

    Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 16, 2024

    blank

    06

    Eisbach Bio

    Denmark
    arrow
    APGA Annual Conference
    Not Confirmed

    Eisbach Bio

    Denmark
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : EIS-12656,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Eisbach Doses First Patient in Phase 1/2 Trial for EIS-12656 in Refractory Solid Tumors

    Details : EIS-12656 targets ALC1 through allosteric mechanisms, suppressing the cancer-relevant genome reorganization induced by DNA damage. This leads to ALC1 chromatin trapping and cancer cell killing.

    Product Name : EIS-12656

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    September 16, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Imfinzi approved in the US for endometrial cancer

    Details:

    Imfinzi (durvalumab) a PD-L1 inhibitor which is approved in combination with Lynparza (olaparib) for the treatment of advanced or recurrent endometrial cancer.


    Lead Product(s): Durvalumab,Carboplatin,Olaparib

    Therapeutic Area: Oncology Brand Name: Imfinzi

    Study Phase: Approved FDFProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 17, 2024

    blank

    07

    AstraZeneca

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    AstraZeneca

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Durvalumab,Carboplatin,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Imfinzi approved in the US for endometrial cancer

    Details : Imfinzi (durvalumab) a PD-L1 inhibitor which is approved in combination with Lynparza (olaparib) for the treatment of advanced or recurrent endometrial cancer.

    Product Name : Imfinzi

    Product Type : Antibody

    Upfront Cash : Inapplicable

    June 17, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Medivir´s licensee, Tango Therapeutics, has Discontinued Development of its TNG348 Program

    Details:

    TNG348 is a novel selective inhibitor of USP1 which is in phase 1/2 clinical trials as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant cancers.


    Lead Product(s): TNG348,Olaparib

    Therapeutic Area: Oncology Brand Name: TNG348

    Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 23, 2024

    blank

    08

    Tango Therapeutics

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Tango Therapeutics

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : TNG348,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Medivir´s licensee, Tango Therapeutics, has Discontinued Development of its TNG348 Program

    Details : TNG348 is a novel selective inhibitor of USP1 which is in phase 1/2 clinical trials as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant cancers.

    Product Name : TNG348

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    May 23, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck Updates On Phase 3 KEYLYNK-006 Trial with KEYTRUDA® Plus LYNPARZA®

    Details:

    Keytruda (pembrolizumab) is being evaluated with Lynparza (olaparib), a PARP inhibitor, for metastatic nonsquamous non-small cell lung cancer.


    Lead Product(s): Pembrolizumab,Olaparib,Pemetrexed

    Therapeutic Area: Oncology Brand Name: Keytruda

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: AstraZeneca

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 21, 2024

    blank

    09

    Merck & Co

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pembrolizumab,Olaparib,Pemetrexed

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : AstraZeneca

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Merck Updates On Phase 3 KEYLYNK-006 Trial with KEYTRUDA® Plus LYNPARZA®

    Details : Keytruda (pembrolizumab) is being evaluated with Lynparza (olaparib), a PARP inhibitor, for metastatic nonsquamous non-small cell lung cancer.

    Product Name : Keytruda

    Product Type : Antibody

    Upfront Cash : Inapplicable

    March 21, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lynparza and Imfinzi Demonstrated Strong Benefit Doubling Median Duration Of Response

    Details:

    Imfinzi (durvalumab) with platinum-based chemotherapy followed by Lynparza (olaparib), demonstrated improved outcomes in patients with mismatch repair proficient advanced endometrial cancer.


    Lead Product(s): Durvalumab,Olaparib

    Therapeutic Area: Oncology Brand Name: Imfinzi

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Merck & Co

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 18, 2024

    blank

    10

    AstraZeneca

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    AstraZeneca

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Durvalumab,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Merck & Co

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Lynparza and Imfinzi Demonstrated Strong Benefit Doubling Median Duration Of Response

    Details : Imfinzi (durvalumab) with platinum-based chemotherapy followed by Lynparza (olaparib), demonstrated improved outcomes in patients with mismatch repair proficient advanced endometrial cancer.

    Product Name : Imfinzi

    Product Type : Antibody

    Upfront Cash : Inapplicable

    March 18, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    INTERMEDIATE SUPPLIERS

    read-more
    read-more

    01

    Allchem Lifescience

    India
    APGA Annual Conference
    Not Confirmed
    arrow

    Allchem Lifescience

    India
    APGA Annual Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    N-Boc-Piperazine

    CAS Number : 57260-71-6

    End Use API : Olaparib

    About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Allchem Lifescience

    India
    APGA Annual Conference
    Not Confirmed
    arrow

    Allchem Lifescience

    India
    APGA Annual Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cyclopropane carboxylic acid

    CAS Number : 1759-53-1

    End Use API : Olaparib

    About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Allchem Lifescience

    India
    APGA Annual Conference
    Not Confirmed
    arrow

    Allchem Lifescience

    India
    APGA Annual Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cyclopropyl Carbonyl Chloride

    CAS Number : 4023-34-1

    End Use API : Olaparib

    About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Allchem Lifescience

    India
    APGA Annual Conference
    Not Confirmed
    arrow

    Allchem Lifescience

    India
    APGA Annual Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    1-Cyclopropyl carbonyl piperazine

    CAS Number : 59878-57-8

    End Use API : Olaparib

    About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Ami Organics Private Limited

    India
    APGA Annual Conference
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    APGA Annual Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    2-FLUORO-5-FORMYL BENZONITRILE

    CAS Number : 218301-22-5

    End Use API : Olaparib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Ami Organics Private Limited

    India
    APGA Annual Conference
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    APGA Annual Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    2-FLUORO-5-((4-OXO-3,4-DIHYDROPHTHALAZIN-1-YL) ME...

    CAS Number : 763114-26-7

    End Use API : Olaparib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Ami Organics Private Limited

    India
    APGA Annual Conference
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    APGA Annual Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    DIMETHYL (3-OXO-1,3-DIHYDRO-2-BENZOFURAN-1-YL) PH...

    CAS Number : 61260-15-9

    End Use API : Olaparib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Ami Organics Private Limited

    India
    APGA Annual Conference
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    APGA Annual Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    CYCLOPROPANECARBONYL CHLORIDE

    CAS Number : 4023-34-1

    End Use API : Olaparib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Ami Organics Private Limited

    India
    APGA Annual Conference
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    APGA Annual Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    CYCLOPROPYL CARBONYL PIPERAZINE

    CAS Number : 59878-57-8

    End Use API : Olaparib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Inventys

    India
    APGA Annual Conference
    Not Confirmed
    arrow

    Inventys

    India
    APGA Annual Conference
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cyclopropane Carboxylic Acid

    CAS Number : 1759-53-1

    End Use API : Olaparib

    About The Company : INVENTYS Research Company – India’s Leading CDMO of Actives, Advanced Intermediates, and Specialty Chemicals. A research-driven Exclusive Synthesis and CDMO...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Coating Systems & Additives

    read-more
    read-more

    Fillers, Diluents & Binders

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Granulation

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Topical

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    US Medicaid Prescriptions

    read-more
    read-more

    01

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Astrazeneca

    Olaparib

    Drug Cost (USD) : 487,431,793

    Year : 2023

    Prescribers : 5974

    Prescriptions : 34461

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Astrazeneca

    Olaparib

    Drug Cost (USD) : 460,720,287

    Year : 2022

    Prescribers : 6026

    Prescriptions : 34404

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Astrazeneca

    Olaparib

    Drug Cost (USD) : 426,649,225

    Year : 2021

    Prescribers : 5905

    Prescriptions : 32292

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Astrazeneca

    Olaparib

    Drug Cost (USD) : 358,856,238

    Year : 2020

    Prescribers : 5337

    Prescriptions : 27233

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Astrazeneca

    Olaparib

    Drug Cost (USD) : 242,845,094

    Year : 2019

    Prescribers : 3908

    Prescriptions : 18317

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Astrazeneca

    Olaparib

    Drug Cost (USD) : 119,106,528

    Year : 2018

    Prescribers : 2051

    Prescriptions : 9055

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Astrazeneca

    Olaparib

    Drug Cost (USD) : 34,328,798

    Year : 2017

    Prescribers : 756

    Prescriptions : 3194

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Astrazeneca

    Olaparib

    Drug Cost (USD) : 48,125,767

    Year : 2016

    Prescribers : 958

    Prescriptions : 4660

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Annual Reports

    read-more
    read-more

    01

    Brand Name : Lynparza

    Olaparib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    AstraZeneca

    Olaparib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 1,776

    2019 Revenue in Millions : 1,198

    Growth (%) : 48

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Lynparza

    Olaparib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Merck

    Olaparib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 725

    2019 Revenue in Millions : 444

    Growth (%) : 63

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Lynparza

    Olaparib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    AstraZeneca

    Olaparib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 2,348

    2020 Revenue in Millions : 1,776

    Growth (%) : 32

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Lynparza

    Olaparib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Merck

    Olaparib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 989

    2020 Revenue in Millions : 725

    Growth (%) : 36

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Lynparza

    Olaparib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Merck & Co.

    Olaparib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 1,116

    2021 Revenue in Millions : 989

    Growth (%) : 13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Lynparza

    Olaparib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    AstraZeneca

    Olaparib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 2,638

    2021 Revenue in Millions : 2,348

    Growth (%) : 12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Lynparza

    Olaparib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    AstraZeneca

    Olaparib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 2,811

    2022 Revenue in Millions : 2,638

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Alliance revenue - Lynparza

    Olaparib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Alliance revenue - Lynparza

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Merck & Co.

    Olaparib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 1,199

    2022 Revenue in Millions : 1,116

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Alliance revenue - Lynparza

    Olaparib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Alliance revenue - Lynparza

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Merck & Co.

    Olaparib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 1,311

    2023 Revenue in Millions : 1,199

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Lynparza

    Olaparib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Lynparza

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    AstraZeneca

    Olaparib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 3,072

    2023 Revenue in Millions : 2,811

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Market Place

    Do you need sourcing support? Ask us

    APIs

    read-more
    read-more
    Brazil.png
    Olaparib API needed in Brazil [ENA21069]
    An independent consultant based in Brazil having 30+ years of experience in the area of sourcing and foreign trade is looking for suppliers of Olaparib API for commercial purposes. The suppliers must support this enquiry with CoA.
    08 Nov 2024

    Reply

    08 Nov 2024

    Reply text-arrow

    Reply Comment (9)

    08 Nov 2024

    Georgia.png
    Various APIs needed in Georgia [ENA14586]
    A company that deals in various pharmaceutical products is looking for suppliers of Various APIs for commercial purpose. The suppliers must support this enquiry with CoA. 1. Piperacillin + Tasobactam API 2. Imipenem + Cilastatin API 3. Sodium Bicarbonate API 4. Pantoprazole API 5. Pembrolizumab API 6. Olaparib API 7. Vandetanib API 8. Imatinib API 9. Bevacizumab API 10. Trastuzumab API
    05 Aug 2022

    Reply

    05 Aug 2022

    Reply text-arrow

    Reply Comment (4)

    05 Aug 2022

    Brazil.png
    Olaparib API needed in Brazil [ENA13652]
    A large pharmaceutical manufacturing company that deals in portfolios like dermatological, cardiological, gynaecological, gastric, oncology, respiratory & CNS is looking for suppliers of Olaparib API for development purpose. The suppliers must support this enquiry with DMF, GMP & CoA.
    17 May 2022

    Reply

    17 May 2022

    Reply text-arrow

    Reply Comment (9)

    17 May 2022

    Bangladesh.png
    Olaparib (1 kg) API needed in Bangladesh [ENA12353]
    A company based in India that deals in the research, development, manufacturing & marketing of various pharmaceutical products for human & veterinary use is looking for suppliers of Olaparib (1 kg) API for commercial purpose. The suppliers must support this enquiry with USDMF & CoA.
    08 Jan 2022

    Reply

    08 Jan 2022

    Reply text-arrow

    Reply Comment (2)

    08 Jan 2022

    japan.png
    Various APIs needed in Japan [ENA11329]
    A company that deals in the export of chemicals & pharmaceutical products is looking for suppliers of Various APIs for development purposes. The required quantity is 500 g & 1 kg for each. The suppliers must support this enquiry with CoA. 1. Olaparib API 2. Ipragliflozin L-proline API 3. Apixaban API
    07 Sep 2021

    Reply

    07 Sep 2021

    Reply text-arrow

    Reply Comment (11)

    07 Sep 2021

    india-flag.png
    Olaparib (5 kg) API needed in India [ENA10786]
    A specialty pharmaceutical organization, which deals in formulation & analytical development of oral dosage forms & injectables is looking for suppliers of Olaparib (5 kg) API for development purpose.
    03 Jul 2021

    Reply

    03 Jul 2021

    Reply text-arrow

    Reply Comment (3)

    03 Jul 2021

    China.png
    Olaparib (25 kg & 90 kg) API needed in China [ENA09421]
    Conier Chem & Pharma, a company that aims to develop and market innovative products is looking for suppliers of Olaparib (25 kg & 90 kg) API. Interested suppliers can contact them via their email: sales03@conier.com.
    06 Jan 2021

    Reply

    06 Jan 2021

    Reply text-arrow

    Reply Comment (5)

    06 Jan 2021

    Bangladesh.png
    Olaparib API (MOQ) needed in Bangladesh [ENA03782]
    The world-class healthcare solution provider which is engaged in the manufacture and marketing of a wide range of therapeutic drugs, bulk pellets and animal health and nutrition products is looking for suppliers of Olaparib API (MOQ) for domestic consumption.
    28 Mar 2019

    Reply

    28 Mar 2019

    Reply text-arrow

    Reply Comment (5)

    28 Mar 2019

    Market Place
    Enquiry// Various Active Pharmaceutical Ingredients needed in Bangladesh [ENA01104]
    Rainbow Pacific Ltd, a distribution company in Bangladesh is looking for suppliers of following APIs for their client: 1. Alectinib HCl INN (Micronized) 50 kg 2. Olaparib 14.5 kg 3. Apixaban 500 g 4. Cabozantinib Malate 4 kg 5. Neratinib Maleate 5 kg 6. Brigatinib 4.5 kg 7. Ponatinib HCl 2.5 kg Interested suppliers should contact Ms Mallika via Email: rainpac1@gmail.com or Tel: 88028033857.
    17 Jul 2018

    Reply

    17 Jul 2018

    Reply text-arrow

    Reply Comment (1)

    17 Jul 2018

    PharmaCompass
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    US Patents

    read-more
    read-more

    01

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Patent Expiration Date : 2027-08-12

    OLAPARIB

    US Patent Number : 8143241

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 206162

    Patent Use Code : U-1634

    Delist Requested :

    Patent Use Description : TREATMENT OF BRCA MUTA...

    Patent Expiration Date : 2027-08-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Patent Expiration Date : 2027-08-12

    OLAPARIB

    US Patent Number : 8071579

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 208558

    Patent Use Code : U-2482

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2027-08-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Patent Expiration Date : 2029-10-07

    OLAPARIB

    US Patent Number : 12144810

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 208558

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2029-10-07

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Patent Expiration Date : 2029-10-07

    OLAPARIB

    US Patent Number : 11633396

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 208558

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2029-10-07

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Patent Expiration Date : 2027-08-12

    OLAPARIB

    US Patent Number : 8071579

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 208558

    Patent Use Code : U-2819

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2027-08-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Patent Expiration Date : 2027-08-12

    OLAPARIB

    US Patent Number : 8071579

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 208558

    Patent Use Code : U-2824

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2027-08-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Patent Expiration Date : 2031-08-04

    OLAPARIB

    US Patent Number : 8859562

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 208558

    Patent Use Code : U-2832

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2031-08-04

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Patent Expiration Date : 2031-08-04

    OLAPARIB

    US Patent Number : 8859562

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 208558

    Patent Use Code : U-2819

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2031-08-04

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Patent Expiration Date : 2027-08-12

    OLAPARIB

    US Patent Number : 8143241

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 208558

    Patent Use Code : U-3631

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2027-08-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    Patent Expiration Date : 2027-08-12

    OLAPARIB

    US Patent Number : 8143241

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 208558

    Patent Use Code : U-2824

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2027-08-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    US Exclusivities

    read-more
    read-more

    ASTRAZENECA

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    I-885
    2025-03-11
    208558
    1
    blank

    01

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    OLAPARIB

    Exclusivity Code : I-885

    Exclusivity Expiration Date : 2025-03-11

    Application Number : 208558

    Product Number : 1

    Exclusivity Details :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ASTRAZENECA

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    I-914
    2026-05-31
    208558
    1
    blank

    02

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    OLAPARIB

    Exclusivity Code : I-914

    Exclusivity Expiration Date : 2026-05-31

    Application Number : 208558

    Product Number : 1

    Exclusivity Details :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ASTRAZENECA

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ODE-226
    2025-12-19
    208558
    1
    blank

    03

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    OLAPARIB

    Exclusivity Code : ODE-226

    Exclusivity Expiration Date : 2025-12-19

    Application Number : 208558

    Product Number : 1

    Exclusivity Details :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ASTRAZENECA

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ODE-283
    2026-12-27
    208558
    1
    blank

    04

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    OLAPARIB

    Exclusivity Code : ODE-283

    Exclusivity Expiration Date : 2026-12-27

    Application Number : 208558

    Product Number : 1

    Exclusivity Details :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ASTRAZENECA

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ODE-306
    2027-05-08
    208558
    1
    blank

    05

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    OLAPARIB

    Exclusivity Code : ODE-306

    Exclusivity Expiration Date : 2027-05-08

    Application Number : 208558

    Product Number : 1

    Exclusivity Details :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ASTRAZENECA

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    I-885
    2025-03-11
    208558
    2
    blank

    06

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    OLAPARIB

    Exclusivity Code : I-885

    Exclusivity Expiration Date : 2025-03-11

    Application Number : 208558

    Product Number : 2

    Exclusivity Details :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ASTRAZENECA

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    I-914
    2026-05-31
    208558
    2
    blank

    07

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    OLAPARIB

    Exclusivity Code : I-914

    Exclusivity Expiration Date : 2026-05-31

    Application Number : 208558

    Product Number : 2

    Exclusivity Details :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ASTRAZENECA

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ODE-226
    2025-12-19
    208558
    2
    blank

    08

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    OLAPARIB

    Exclusivity Code : ODE-226

    Exclusivity Expiration Date : 2025-12-19

    Application Number : 208558

    Product Number : 2

    Exclusivity Details :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ASTRAZENECA

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ODE-283
    2026-12-27
    208558
    2
    blank

    09

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    OLAPARIB

    Exclusivity Code : ODE-283

    Exclusivity Expiration Date : 2026-12-27

    Application Number : 208558

    Product Number : 2

    Exclusivity Details :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ASTRAZENECA

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    OLAPARIB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ODE-306
    2027-05-08
    208558
    2
    blank

    10

    ASTRAZENECA

    OLAPARIB

    arrow
    APGA Annual Conference
    Not Confirmed

    ASTRAZENECA

    United Kingdom
    arrow
    APGA Annual Conference
    Not Confirmed

    OLAPARIB

    Exclusivity Code : ODE-306

    Exclusivity Expiration Date : 2027-05-08

    Application Number : 208558

    Product Number : 2

    Exclusivity Details :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Looking for 763113-22-0 / Olaparib API manufacturers, exporters & distributors?

    Olaparib manufacturers, exporters & distributors 1

    78

    PharmaCompass offers a list of Olaparib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Olaparib manufacturer or Olaparib supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Olaparib manufacturer or Olaparib supplier.

    PharmaCompass also assists you with knowing the Olaparib API Price utilized in the formulation of products. Olaparib API Price is not always fixed or binding as the Olaparib Price is obtained through a variety of data sources. The Olaparib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Olaparib

    Synonyms

    763113-22-0, Lynparza, Azd2281, Azd-2281, Ku-0059436, Azd 2281

    Cas Number

    763113-22-0

    Unique Ingredient Identifier (UNII)

    WOH1JD9AR8

    About Olaparib

    Olaparib is a small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.

    Olaparib Manufacturers

    A Olaparib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Olaparib, including repackagers and relabelers. The FDA regulates Olaparib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Olaparib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Olaparib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Olaparib Suppliers

    A Olaparib supplier is an individual or a company that provides Olaparib active pharmaceutical ingredient (API) or Olaparib finished formulations upon request. The Olaparib suppliers may include Olaparib API manufacturers, exporters, distributors and traders.

    click here to find a list of Olaparib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Olaparib USDMF

    A Olaparib DMF (Drug Master File) is a document detailing the whole manufacturing process of Olaparib active pharmaceutical ingredient (API) in detail. Different forms of Olaparib DMFs exist exist since differing nations have different regulations, such as Olaparib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Olaparib DMF submitted to regulatory agencies in the US is known as a USDMF. Olaparib USDMF includes data on Olaparib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Olaparib USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Olaparib suppliers with USDMF on PharmaCompass.

    Olaparib KDMF

    In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

    Pharmaceutical companies submit a Olaparib Drug Master File in Korea (Olaparib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Olaparib. The MFDS reviews the Olaparib KDMF as part of the drug registration process and uses the information provided in the Olaparib KDMF to evaluate the safety and efficacy of the drug.

    After submitting a Olaparib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Olaparib API can apply through the Korea Drug Master File (KDMF).

    click here to find a list of Olaparib suppliers with KDMF on PharmaCompass.

    Olaparib WC

    A Olaparib written confirmation (Olaparib WC) is an official document issued by a regulatory agency to a Olaparib manufacturer, verifying that the manufacturing facility of a Olaparib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Olaparib APIs or Olaparib finished pharmaceutical products to another nation, regulatory agencies frequently require a Olaparib WC (written confirmation) as part of the regulatory process.

    click here to find a list of Olaparib suppliers with Written Confirmation (WC) on PharmaCompass.

    Olaparib NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Olaparib as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Olaparib API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Olaparib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Olaparib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Olaparib NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Olaparib suppliers with NDC on PharmaCompass.

    Olaparib GMP

    Olaparib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Olaparib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Olaparib GMP manufacturer or Olaparib GMP API supplier for your needs.

    Olaparib CoA

    A Olaparib CoA (Certificate of Analysis) is a formal document that attests to Olaparib's compliance with Olaparib specifications and serves as a tool for batch-level quality control.

    Olaparib CoA mostly includes findings from lab analyses of a specific batch. For each Olaparib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Olaparib may be tested according to a variety of international standards, such as European Pharmacopoeia (Olaparib EP), Olaparib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Olaparib USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search